Propionyl-l-carnitine in intermittent claudication: Double-blind, placebo-controlled, dose titration, multicenter study

The aim of this double-blind, placebo-controlled, dose titration, multicenter trial was to assess the efficacy and safety of propionyl-l-carnitine in intermittent claudication. Human and animal studies indicate that propionyl-l-carnitine increases carnitine content and improves energy metabolism in...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 1995-11, Vol.26 (6), p.1411-1416
Main Authors: Brevetti, Gregorio, Perna, Sergio, Sabbá, Carlo, Martone, Vincenzo Domenico, Condorelli, Mario
Format: Article
Language:English
Subjects:
Administration, Oral
Analysis of Variance
Cardiotonic Agents - administration & dosage
Cardiotonic Agents - adverse effects
Carnitine - administration & dosage
Carnitine - adverse effects
Carnitine - analogs & derivatives
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Female
Humans
Intermittent Claudication - drug therapy
Male
Middle Aged
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this double-blind, placebo-controlled, dose titration, multicenter trial was to assess the efficacy and safety of propionyl-l-carnitine in intermittent claudication. Human and animal studies indicate that propionyl-l-carnitine increases carnitine content and improves energy metabolism in the ischemic skeletal muscle. After a 2-week preliminary period to assess maximal walking distance, 245 patients were randomly assigned to receive propionyl-l-carnitine (n = 118) or placebo (n = 127). The initial oral dose of 500 mg twice daily was increased at 2-month intervals to 2 g/day and then to 3 g/day in patients showing improvement in treadmill performance
ISSN:0735-1097
1558-3597
DOI:10.1016/0735-1097(95)00344-4